Feature | March 26, 2015

FDA Updates MQSA Facility Certification Extension Requirements for Digital Breast Tomosynthesis Systems

FDA, MQSA, tomosynthesis, DBT, certificate extension, requirements

March 26, 2015 — The U.S. Food and Drug Administration (FDA) released updated requirements for a mammography facility to extend its Mammography Quality Standards Act (MQSA) certification for digital breast tomosynthesis (DBT) systems.

All of the following information must be included with the application:

1: Manufacturers name of FFDM-DBT unit

2. Facility Status Information

a. Facility Name and FDA Facility ID Number
b. FDA Certificate Expiration Date
c. Current Accreditation Body for the 2D unit
d. Accreditation Expiration Date
e. Facility Contact Person for DBT unit
f. Contact Person’s Title
g. Contact Person’s Telephone, Fax, E-mail
h. Facility Address
i. Facility Owner

3. DBT Unit Identification

a. Machine Manufacturer
b. Machine Model
c. Year of Manufacture
d. Serial Number
e. Accreditation Body Unit Number

4. DBT Digital Image Receptor Identification (if interchangeable)

a. Receptor Manufacturer
b. Receptor Model
c. Year of Manufacture
d. Serial Number (if applicable)

5. Identification of Printer for Hard Copy Interpretation (mandatory even for facilities performing only soft copy interpretation)

a. Printer Manufacturer
b. Printer Model
c. Year of Manufacture
d. Serial Number

6. Final Interpretation Review Monitor Identification (if soft copy display is available)

a. Monitor Manufacturer
b. Monitor Model
c. Year of Manufacture
d. Serial Number

7. Phantom Identification

a. Phantom Manufacturer
b. Phantom Model

8. Hardcopy phantom image (3D mode) must be included when submitting application.

9. Personnel Qualifications

a. Interpreting Physicians who are qualified to interpret DBT mammograms (see Qualified Personnel)
b. Radiological Technologists who are qualified to perform DBT mammography examinations and the manufacturer recommended quality assurance tests (see Qualified Personnel)
c. Medical Physicists who are qualified to perform equipment evaluations and/or surveys of DBT mammography units (Qualified Personnel)

10. Complete Detailed report of Mammography Equipment Evaluation (MEE) (must have been conducted in accordance with 900.12(e)(10) within the 6 months prior to the request for use approval) must be included when submitting application.

a. Statement that equipment performance, as required under the following sections of the
MQSA final regulation 21 CFR 900.12(b), is met:

(1) Prohibited Equipment
(2) Specifically Designed for Mammography
(3) Motion of Tube-Image Receptor Assembly
(4)(iii) Removable Grid (if applicable to the DBT system used) (5) Beam Limitation and Light Fields
(6) Magnification
(7) Focal Spot Selection
(8) Compression
(9) Technique Factor Selection and Display
(10) Automatic Exposure Control

b. The results of quality control tests as required under the following sections of the
MQSA final regulations 21CFR 900.12(e):

(4)(iii) Compression Device Performance
(5)(i) Automatic Exposure Control Performance (if applicable to the DBT system used) (5)(ii) Kilovoltage Peak Accuracy and Reproducibility
(5)(iii) Focal Spot Condition (Resolution) (5)(iv) Beam Quality and Half-Value Layer
(5)(v) Breast Entrance Air Kerma and AEC Reproducibility (if applicable to the DBT
system used) (5)(vi) Dosimetry
(5)(vii) X-Ray Field/Light field/Image receptor/Compression paddle alignment
(5)(ix) System Artifacts
(5)(x) Radiation Output
(5)(xi) Decompression (or alternative standards allowed for these requirements) (6) Quality Control Tests – Other Modalities (Facilities must perform all DBT manufacturer recommended quality control tests including the medical physicist’s tests for Soft Copy Display system)

c. The results of the phantom image quality tests, including a sample image
d. If any of the requirements in 8 a, b, or c are not met, submit documentation of successful corrective action
e. If any of the requirements in 8 a or b are not performed, explain why the requirement is not applicable
f. Date of the MEE
g. Name and address of the physicist(s) who performed the MEE

11. DBT Manufacturer’s Quality Control Program

a. Name of the Quality Control Manual
b. Year published
c. Revision number, if not the original
d. Printing number, if not the original

12. Signature of facility contact person for the DBT unit


Note 1: Under MQSA, each manufacturer’s Digital Breast Tomosynthesis system is currently considered a separate new mammographic modality, and the personnel requirements for new modality training apply.

Note 2: In order to use the tomosynthesis portion of the unit, the facility must apply to FDA to have its certificate extended to include that portion of the unit. The certification extension only applies to the DBT portion of the unit. The facility must have the 2-D portion of the unit accredited by one of the accreditation bodies already approved to accredit the 2-D portion.

For more information: www.fda.gov

Related Content

Genia Sutton, intGenia Sutton, interim director of radiology

Genia Sutton, interim director of radiology, has seen the benefit to patients. “Five minutes is a lot of time if you are thinking you may have breast cancer,” she said. “Now, technologists aren’t as rushed. They can give a more personal touch because they can spend more time with their patients.”

Sponsored Content | Case Study | Mammography | October 10, 2019
When Cullman Regional Medical Center in Alabama decided to
Breast cancer awareness month is October
News | Clinical Case Studies | October 03, 2019
A decades-long decline in the breast cancer death rate continues, but has begun to slow in recent years, while breast
Volpara's breast density scale

Levels of breast density.

News | Women's Health | October 01, 2019
Celebrating its 10th Anniversary in 2019,...
Discomfort May Deter Large Number of Women From Obtaining Mammograms
News | Mammography | September 25, 2019
Siemens Healthineers and national nonprofit HealthyWomen announced results from a new national survey designed to...
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Ashley County Medical Center Installs Arkansas' First Fujifilm Aspire Cristalle With DBT
News | Mammography | August 27, 2019
Fujifilm Medical Systems U.S.A. Inc. recently announced that Ashley County Medical Center (Crossett, Ark.) has invested...
Sectra Signs Enterprise Imaging Contract With Vanderbilt Health
News | Enterprise Imaging | August 21, 2019
Sectra will install its enterprise imaging picture archiving and communication system (PACS) and vendor neutral archive...
Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...